BioCryst Pharma (BCRX) Climbs 12.5% Following Successful Proof of Concept for Oral Factor D Inhibitor, BCX9930
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
BioCryst Pharma (NASDAQ: BCRX) Climbs 12.5% Following Successful Proof of Concept for Oral Factor D Inhibitor, BCX9930
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Affimed (AFMD) Climbs 40% Following Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
- Yatra Online (YTRA) Gains as Activist Maguire Asset Management Files 13D, Letter to CEO
- Boeing (BA) 737 Max Electrical Issue Impacts About 90 Airplanes - Reuters